ArticleClinical & experimental metastasis2007
A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate.
Article in Clinical & experimental metastasis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- Osteolytic Bone Metastasis: Different Radiotherapy Fractionation Schedules Compared Clinically and Radiographically.Current oncology (Toronto, Ont.) · 2024Trial
- Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.Journal of cancer research and clinical oncology · 2008Trial
- Computed tomography Hounsfield unit values as a treatment response indicator for spinal metastatic lesions in patients with non-small-cell lung cancer: a retrospective study in Japan.Asian spine journal · 2025Article
- Review
- Reliability of Alkaline Phosphatase for Differentiating Flare Phenomenon from Disease Progression with Bone Scintigraphy.Cancers · 2022Article
- Density of bone metastatic lesions increases after radiotherapy in patients with breast cancer.Journal of radiation research · 2019Article
- Bone Density as a Marker of Response to Radiotherapy in Bone Metastatic Lesions: A Review of the Published Data.International journal of molecular sciences · 2016Review
- Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Review
- Follow-up CT and MR findings of osteoblastic spinal metastatic lesions after stereotactic radiotherapy.Japanese journal of radiology · 2012Article
- Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Review
- Article
- Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria.British journal of cancer · 2010Article
- Types of bone metastases in women with breast cancer undergoing systemic treatments.La Radiologia medica · 2008Article
- Impact of skeletal complications on patients' quality of life, mobility, and functional independence.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2008Review
- Advances in radiation therapy for oncologic pain.Current pain and headache reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the therapeutic response of patients with different types of bone metastases treated with combined radiotherapy and bisphosphonates. PATIENTS AND
methodsBy using computed tomography 52 patients were grouped into groups of lytic, mixed and sclerotic bone lesions. All patients were treated with concomitant radiotherapy and ibandronate (10 monthly cycles) and underwent clinical and radiological evaluations prior to therapy and at 3, 6 and 10 months of follow up.
resultsAt baseline there were statistically significant differences between the three groups for all the evaluated parameters. From 3 months onwards differences were leveled out. Statistically significant improvements were noted at all time points of evaluation for all groups in parameters such as pain (0-10), quality of life (QOL-physical functioning, 0-100) and Karnofsky performance status (KPS). The average pain score for the lytic group was reduced from 8.1 to 1.5 points at 3 months. The corresponding reductions for the mixed and sclerotic groups were from 6.2 to 0.5 and from 4.4 to 0.3 points respectively. Complete pain responses were >76.4% at all time points for all groups. Opioid consumption was also markedly reduced. Overall, the highest clinical response was noted for the lytic group, even though the mean values of pain, QOL and KPS were worse than those of the two other groups at all time points (apart from pain score at 10 months). The percentage of patients of the lytic group experiencing a complete pain response was the least of the three groups during follow up. At 10 months bone density was almost tripled for the lytic and almost doubled for the mixed group.
conclusionsEven though the therapeutic outcome for the three groups was similar, the degree of clinical response and reossification differed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.